Implementation of the Addendum Guidelines for Peanut Allergy Prevention by US allergists, a survey conducted by the NIAID, in collaboration with the AAAAI - 05/10/20
, Ruchi S. Gupta, MD, MPH b, c, Lucy A. Bilaver, PhD c, Jack W. Hu, MS a, Jennifer Martin, BS a, Jialing Jiang, BA c, Alexandria Bozen, BS c, Matthew M. Davis, MD, MAPP b, c, Jamie Reese, BS a, Susan Cooper, MSc d, Alkis Togias, MD, FAAAAI d, Samuel J. Arbes, PhD aAbstract |
Background |
In 2017, the Addendum Guidelines for the Prevention of Peanut Allergy were published with recommendations on early introduction of peanut-containing foods based on infants’ clinical history.
Objective |
We sought to conduct a nationwide US survey to assess Guidelines implementation among allergists and immunologists who manage infants for food allergy.
Methods |
Survey invitations were delivered to 3281 nonretired, US members of the American Academy of Asthma, Allergy & Immunology, board certified in allergy and immunology. The survey assessed awareness and implementation of the Guidelines and barriers to implementation. Descriptive statistics were generated.
Results |
Twenty-nine percent (946 of 3281) of surveyed allergists/immunologists responded, and 87.1% (825 of 946) of responders met eligibility criteria. Among eligible responders, 97.1% were aware of the Guidelines. Of these, 64.5% reported full implementation of the Guidelines as published, 34.4% reported partial implementation, and 1.1% reported using none of the Guidelines. Barriers to Guidelines use included parental (47.6%) and self (21.8%) concerns about allergic reactions, lack of referrals (33.6%), parents uninterested in early feeding (28.2%), and lack of clinic time (20.9%). The 2 most common deviations from the Guidelines were considering additional factors not specified in the Guidelines such as family history (50.2%) and conducting skin prick testing in non–high-risk children (43.9%). Of respondents using the Guidelines, 45.7% indicated they needed more education or training.
Conclusions |
Essentially all allergists/immunologists who responded to the survey reported full or partial Guidelines implementation. Parental concerns and lack of referrals are major identifiable barriers. Improved Guidelines messaging to parents and referring physicians is warranted.
Le texte complet de cet article est disponible en PDF.Key words : Peanut allergy, food allergy, prevention guidelines, clinical practice, survey
Abbreviations used : AAAAI, LEAP
Plan
| This study was funded by the National Institute of Allergy and Infectious Diseases (grant no. 1UM2AI117870-04). |
|
| A. Togias’ and S. Cooper’s coauthorship on this publication does not constitute endorsement by the US National Institute of Allergy and Infectious Diseases or by any other US government agency. |
|
| Disclosure of potential conflict of interest: R. S. Gupta reports receiving grants from the National Institutes of Health (grant nos. R21 ID# AI135705, R01 ID# AI130348, and U01 ID# AI138907), Rho, Inc, Stanford Sean N. Parker Center for Allergy Research, UnitedHealth Group, Thermo Fisher Scientific, Genentech, and the National Confectioners Association; and serves as a medical consultant/advisor for Before Brands, Kaléo, Inc, Genentech, Institute for Clinical and Economic Review, Food Allergy Research & Education, Aimmune Therapeutics, and DBV Technologies. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 146 - N° 4
P. 875-883 - octobre 2020 Retour au numéro
Article précédent
- Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results
- David M. Fleischer, Wayne G. Shreffler, Dianne E. Campbell, Todd D. Green, Sara Anvari, Amal Assa’ad, Philippe Bégin, Kirsten Beyer, J. Andrew Bird, Terri Brown-Whitehorn, Aideen Byrne, Edmond S. Chan, Amarjit Cheema, Sharon Chinthrajah, Hey Jin Chong, Carla M. Davis, Lara S. Ford, Rémi Gagnon, Matthew Greenhawt, Jonathan O’B. Hourihane, Stacie M. Jones, Edwin H. Kim, Lars Lange, Bruce J. Lanser, Stephanie Leonard, Vera Mahler, Andreas Maronna, Anna Nowak-Wegrzyn, Roxanne C. Oriel, Michael O’Sullivan, Daniel Petroni, Jacqueline A. Pongracic, Susan L. Prescott, Lynda C. Schneider, Peter Smith, Doris Staab, Gordon Sussman, Robert Wood, William H. Yang, Romain Lambert, Aurélie Peillon, Timothée Bois, Hugh A. Sampson
- Omeprazole inhibits IgE-mediated mast cell activation and allergic inflammation induced by ingested allergen in mice
- Cynthia Kanagaratham, Yasmeen S. El Ansari, Benjamin F. Sallis, Brianna-Marie A. Hollister, Owen L. Lewis, Samantha C. Minnicozzi, Michiko K. Oyoshi, Rachel Rosen, Samuel Nurko, Edda Fiebiger, Hans C. Oettgen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?